Eli Lilly and Company Opens Eco-Friendly Biotechnology Center on the West Coast Designed to Speed and Enhance ... ( SAN DIEGO Oct. 29 /- As part of its s...)

HOME >> MEDICINE >> TECHNOLOGY

Eli Lilly and Company Opens Eco-Friendly Biotechnology Center on the West Coast Designed to Speed and Enhance Innovation

Date:10/29/2009

SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- As part of its strategy to discover and develop more biotechnology medicines, Eli Lilly and Company today officially opened a new state-of-the-art biotechnology center on the West Coast. The facility, known as the "Lilly Biotechnology Center - San Diego," is opening three months after Lilly announced it is moving its ImClone research headquarters (which specializes in developing cancer biologics) into a new biopharmaceutical research cluster in New York, and just one year after Lilly completed construction of its biotechnology research and development complex at company headquarters in Indianapolis, Indiana.

"We are moving full speed ahead toward building a biotechnology powerhouse," said John Lechleiter, Ph.D., Lilly chairman and chief executive officer. "The science, technology and talent at our new center in San Diego will help bring novel biotech medicines to patients faster and more efficiently, and reinforces Lilly's commitment and contributions to San Diego's burgeoning bioscience industry."

Lilly's latest biotechnology center is located within an extensive hub of life science activity near the University of California, San Diego and other prominent biomedical research institutes, which is consistent with Lilly's FIPNet strategy to leverage external resources and knowledge to advance its pipeline.

Of the nearly 200 scientists based at the center, more than half are from Applied Molecular Evolution (AME), a wholly-owned Lilly subsidiary that discovers, engineers and develops biotechnology-based therapies built specifically from human proteins. Additionally, the center is the work base for scientists from discovery chemistry research and technology (DCRT), a division within Lilly that includes scientists from what was previously known as SGX Pharmaceuticals. (Lilly acquired SGX in 2008 and incorporated it into DCRT.)

Lilly's West Coast'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Lilly Surpasses Energy Efficiency Goals and Celebrates Worldwide Energy Day
2. Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance
3. Lilly Declares Fourth-Quarter Dividend
4. Lilly to Sell Tippecanoe Manufacturing Site to Evonik Industries
5. Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs
6. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
7. Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
8. Study Showed Lillys GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients
9. Lilly Advances Second Alzheimers Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials
10. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
11. Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research

Post Your Comments:

(Date:2/8/2010)... 8 Cost reductions offset a recession-driven ... AHPI ) narrowly back into profitability in the second ... quarter ended December 31, 2009 declined almost ... the same quarter last year to $11.4 million ... sales were reduced even more sharply, from approximately ...

(Date:2/8/2010)... N.J. , Feb. 8 Savient ... the company will release financial results for the fourth ... market on Thursday, February 25, 2010 . ... Group Vice President and Chief Financial Officer, will host ... a.m. Eastern Time on February 26, 2010 ...

(Date:2/8/2010)... Hanger Orthopedic Group, Inc. (NYSE: HGR ) announced ... for the year ended December 31, 2009 , on ... to issue a press release announcing the results for the ... February 10, 2010 , after the close of the market. ... a.m., EST , on Thursday, February 11, 2010 . ...

Breaking Medicine Technology:Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 2 Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 3 Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 4 Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 5 Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 6 Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010 2 Hanger Orthopedic Group, Inc. Announces 2009 Year-End Earnings Release Conference Call 2 ReSearch Pharmaceutical Services Inc to Present at Jefferies 2010 Global Healthcare Conference 65027 1 ReSearch Pharmaceutical Services Inc to Present at Jefferies 2010 Global Healthcare Conference 65027 2 The Advisory Board Company Schedules Third Quarter Conference Call for February 4 2010 15383 1 The Advisory Board Company Schedules Third Quarter Conference Call for February 4 2010 15383 2 Clinical Data Presented at Asia PCR Sing LIVE Demonstrate Benefits of OrbusNeichs Genous 28TM 29 Bio engineered R stent 28TM 29 in Challenging Patient 7462 1 Clinical Data Presented at Asia PCR Sing LIVE Demonstrate Benefits of OrbusNeichs Genous 28TM 29 Bio engineered R stent 28TM 29 in Challenging Patient 7462 2 Clinical Data Presented at Asia PCR Sing LIVE Demonstrate Benefits of OrbusNeichs Genous 28TM 29 Bio engineered R stent 28TM 29 in Challenging Patient 7462 3 Clinical Data Presented at Asia PCR Sing LIVE Demonstrate Benefits of OrbusNeichs Genous 28TM 29 Bio engineered R stent 28TM 29 in Challenging Patient 7462 4

[0] Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions [0] Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010 [0] Hanger Orthopedic Group, Inc. Announces 2009 Year-End Earnings Release Conference Call

... 16 Anthera Pharmaceuticals,Inc., a privately held ... after completing its review,of safety and efficacy ... Board (DSMB) has recommended that Anthera,s Phase ... of the Modulation of,Phospholipase in Acute ChesT ...

... Treximet provided significantly more patients ... sumatriptan 85 mg, LONDON, April 15 GlaxoSmithKline (LSE: ... ) announced today that the FDA has,approved Treximet for the ... Treximet is the first and only migraine product,designed to target ...

Other Medicine Technology:DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease 2 Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine 2 Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine 3 Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine 4 Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine 5 Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine 6 Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine 7

DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine

(Date:2/9/2010)... more weight than peers who tried lifestyle changes , , ... who received gastric banding surgery lost significantly more weight ... and exercise, Australian researchers report. , Their study included ... index (BMI) higher than 35 (statistical obesity begins at ... banding while the other half took part in a ...

(Date:2/9/2010)... more likely to insert them , , TUESDAY, Feb. 9 ... set up to make a profit are more likely ... despite evidence that the practice does not prolong life ... "Our results suggest that decisions about feeding tubes are ... decision-making process that really elicits and supports patient choice," ...

(Date:2/9/2010)... PAUL, Minn. , Feb. 9 /PRNewswire-USNewswire/ ... chronic obstructive pulmonary disease (COPD), is now being ... Public Health Tracking Program. The program focuses on ... that can be triggered or made worse ... outdoor air pollution — asthma, heart attacks and ...

(Date:2/9/2010)... the Heart with "The Heart-Smart Diabetes Kitchen" ... Show your love this Valentine,s ... the heart with the new cookbook "The Heart-Smart Diabetes ... Oil" by the American Diabetes Association (ADA) and CanolaInfo. ... or give the cookbook as a gift, you will ...

(Date:2/9/2010)... In conjunction with the 2010 Super Bowl, ... (LSI) sponsored the first-annual Gridiron Greats Night of Champions, a ... Mike Ditka and Jamie Foxx . Supported ... Greats is a non-profit organization that provides financial assistance and ... This year, Gridiron Greats recognized LSI at the event as ...

Breaking Medicine News(10 mins):Health News:Gastric Banding Most Effective for Obese Teens 2 Health News:Too Many With End-Stage Dementia Get Feeding Tubes 2 Health News:Too Many With End-Stage Dementia Get Feeding Tubes 3 Health News:Minnesota Department of Health Report: Nearly 6,000 Hospitalizations for COPD in 2007 2 Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 2 Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 3 Health News:Laser Spine Institute Honored at the Gridiron Greats Night of Champions 2

[0] Gastric Banding Most Effective for Obese Teens [0] Too Many With End-Stage Dementia Get Feeding Tubes [0] Minnesota Department of Health Report: Nearly 6,000 Hospitalizations for COPD in 2007 [0] Cook With Love This Valentine's Day With Heart-Smart Recipes [0] Laser Spine Institute Honored at the Gridiron Greats Night of Champions

... in New Television Ad, SACRAMENTO, Calif., Oct. 28 ... new television spot featuring Senator Diane Feinstein,who, speaking directly ... mistake for California. It,s about discrimination and we must,always ... to have the strong, trusted and independent voice of,Senator ...

... study found , , TUESDAY, Oct. 28 (HealthDay News) -- ... one-third lower for those taking statins than for those ... , While the findings are preliminary and offer hope, ... as infection fighters, experts said. , "I think we ...

... Complaint Alleges Defamation, Trade Libel and Intentional Interference with ... Prospective ... BPUR ) announced today that it had filed an ... co-authored an,article and several letters about Hemopure, hemoglobin glutamer-250,(bovine), Biopure,s ...

... Sales Grow 52% Worldwide, 24% in U.S. ... Cost Reduction Efforts Continue to Generate Results ... by 29%, Company Completes Clinical Data Step for Visian Toric ICL Application to ... FDA, ...

... worsens, research shows , , TUESDAY, Oct. 28 (HealthDay News) ... gum disease, a U.S. study finds. , Previous research ... a condition where chronic inflammation results in the separation ... support, and possible tooth loss. , In this new ...

... 28 Blue Mountain Quality,Resources, Inc. announced ... Regulatory Asset Manager(R) to satisfy their immediate ... their enterprise-wide,SAP(R) implementation., "Alexion is committed ... in,its manufacturing facilities and other operations," explains ...

Senator Dianne Feinstein Denounces Prop 8 Statins Reduced Death Risk From Pneumonia Biopure Sues National Institutes of Health Official STAAR Surgical Reports 33% Third Quarter Revenue Growth Rheumatoid Arthritis May Harm Gums Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R)

... ELISA test for Clostridium difficile antigen that ... sensitivity. That means the laboratory can quickly, ... negatives - which can represent up to ... the organism - and be sure that ...

... test is a rapid immunoassay to detect Clostridium ... The test uses antibodies specific for toxins A ... sensitivity and >99% specificity compared to tissue culture. ... toxin B, the risk of false negative results ...

... autoimmune testing feature single-well ANA screen and ... reflex tests including dsDNA, and 6 individual ... (La), Scl-70 and Jo-1. In addition, our ... of products for Cardiolipins (IgA, IgG, IgM), ...

... for autoimmune testing feature single-well ANA screen ... specific reflex tests including dsDNA, and 6 ... SS-B (La), Scl-70 and Jo-1. In addition, ... line of products for Cardiolipins (IgA, IgG, ...

Medicine Products:

C. Diff-CHEK-30 TOX A/B QUIK CHEK Gliadin IgA II Cardiolipin IgG, A, M

Eli Lilly and Company Opens Eco-Friendly Biotechnology Center on the West Coast Designed to Speed and Enhance ...( SAN DIEGO Oct. 29 /- As part of its s...),Health